» Articles » PMID: 25856680

The Photodynamic Antibacterial Effects of Silicon Phthalocyanine (Pc) 4

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2015 Apr 10
PMID 25856680
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The emergence of antibiotic-resistant strains in facultative anaerobic Gram-positive coccal bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), is a global health issue. Typically, MRSA strains are found associated with institutions like hospitals but recent data suggest that they are becoming more prevalent in community-acquired infections. It is thought that the incidence and prevalence of bacterial infections will continue to increase as (a) more frequent use of broad-spectrum antibiotics and immunosuppressive medications; (b) increased number of invasive medical procedures; and (c) higher incidence of neutropenia and HIV infections. Therefore, more optimal treatments, such as photodynamic therapy (PDT), are warranted. PDT requires the interaction of light, a photosensitizing agent, and molecular oxygen to induce cytotoxic effects. In this study, we investigated the efficacy and characterized the mechanism of cytotoxicity induced by photodynamic therapy sensitized by silicon phthalocyanine (Pc) 4 on (a) methicillin-sensitive Staphylococcus aureus (MSSA) (ATCC 25923); (b) community acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) (ATCC 43300); and (c) hospital acquired methicillin-resistant Staphylococcus aureus (HA-MRSA) (PFGE type 300). Our data include confocal image analysis, which confirmed that Pc 4 is taken up by all S. aureus strains, and viable cell recovery assay, which showed that concentrations as low as 1.0 μM Pc 4 incubated for 3 h at 37 °C followed by light at 2.0 J/cm2 can reduce cell survival by 2-5 logs. These results are encouraging, but before PDT can be utilized as an alternative treatment for eradicating resistant strains, we must first characterize the mechanism of cell death that Pc 4-based PDT employs in eliminating these pathogens.

Citing Articles

Antimicrobial Photodynamic Therapy against and Using Nanoemulsion-Encapsulated Zinc Phthalocyanine.

Felifel N, Sliem M, Kamel Z, Bojarska J, Seadawy M, Amin R Microorganisms. 2023; 11(5).

PMID: 37317117 PMC: 10222491. DOI: 10.3390/microorganisms11051143.


Photophysics of tetracarboxy-zinc phthalocyanine photosensitizers.

Potlog T, Popusoi A, Lungu I, Robu S, Bulimestru I RSC Adv. 2022; 12(49):31778-31785.

PMID: 36380933 PMC: 9639198. DOI: 10.1039/d2ra05676c.


Turning Photons into Drugs: Phthalocyanine-Based Photosensitizers as Efficient Photoantimicrobials.

Galstyan A Chemistry. 2020; 27(6):1903-1920.

PMID: 32677718 PMC: 7894475. DOI: 10.1002/chem.202002703.


Photodynamic Therapy for Cancer: What's Past is Prologue.

Hamblin M Photochem Photobiol. 2019; 96(3):506-516.

PMID: 31820824 PMC: 7282978. DOI: 10.1111/php.13190.


Synthesis of an Activatable Tetra-Substituted Nickel Phthalocyanines-4(3H)-quinazolinone Conjugate and Its Antibacterial Activity.

Elsharif A, Youssef T, Al-Jameel S, Mohamed H, Ansari M, Rehman S Adv Pharmacol Sci. 2019; 2019:5964687.

PMID: 31143208 PMC: 6501279. DOI: 10.1155/2019/5964687.


References
1.
Taub A . Photodynamic therapy: other uses. Dermatol Clin. 2006; 25(1):101-9. DOI: 10.1016/j.det.2006.09.007. View

2.
Styers D, Sheehan D, Hogan P, Sahm D . Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob. 2006; 5:2. PMC: 1397857. DOI: 10.1186/1476-0711-5-2. View

3.
Kurlenda J, Grinholc M . Alternative therapies in Staphylococcus aureus diseases. Acta Biochim Pol. 2012; 59(2):171-84. View

4.
Steinkraus G, White R, Friedrich L . Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007; 60(4):788-94. DOI: 10.1093/jac/dkm258. View

5.
van Hal S, Fowler Jr V . Reply to Parra-Ruiz. Clin Infect Dis. 2013; 57(8):1219-20. DOI: 10.1093/cid/cit460. View